1250 Hancock Street, Suite 210N
Tel: (781) 562-1170
Abveris is a premier antibody discovery partner, offering end-to-end mAb discovery solutions to biotech and biopharma companies of all sizes. Our process starts with a thorough project design process, where we work collaboratively with our partners to design a project with the greatest likelihood of success.
Whether you need functional antibodies or you're targeting complex cell surface targets, our technical teams and project managers help deliver the diverse panels of functionally relevant antibodies that meet your project needs. Our services give our partners access to multiple technology platforms with optimized workflows for immunizations, screening, characterization, sequencing, purification, and recombinant production.
15 articles with Abveris
The Business Intelligence Group today announced that it has awarded Abveris a division of Twist Bioscience, a Best Places to Work 2022.
Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities
Twist Bioscience Corporation today announced it entered into a definitive agreement to acquire Abveris.
Twist Bioscience snapped up in vivo antibody discovery company Abveris Inc. in a deal valued at up to $190 million. The acquisition is expected to bolster Twist’s biopharma antibody capabilities.
Abveris Announces Multi-Target, Multi-Year Therapeutic Antibody Discovery Collaboration with Prometheus Biosciences
Abveris today announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets.
Abveris and Abilita Bio Announce a Discovery Collaboration to Develop Therapeutics for Challenging Membrane Protein Targets
Abveris, Inc. ("Abveris") and Abilita Bio, Inc. announce a joint research collaboration that will leverage the synergies between their platforms to enable the discovery of novel antibodies targeting key GPCRs within the tumor immune microenvironment.
Abveris Announces Partnership with Foundery Innovations to Develop Therapeutics to Advance Immunotherapy
Abveris, Inc. ("Abveris") announced today that it has entered into an antibody discovery partnership with Foundery Innovations, Inc. ("Foundery Innovations") for the discovery of monoclonal antibodies to support the development of novel biotherapeutic drugs.
Abveris Deploys Second Berkeley Lights Beacon® System to Expand Single B Cell Antibody Discovery Capacity
Abveris, Inc., Boston's leader in antibody discovery services, today announced the deployment of a second Berkeley Lights, Inc. Beacon® optofluidic system to enable expansion of the Abveris antibody discovery offering.
Abveris Presents Integrated Antibody Discovery Workflows Targeting the SARS-CoV-2 Spike Protein for COVID-19 Research
Abveris, Inc. today announced the release of antibody sequences specific to the SARS-CoV-2 spike (S) protein into the public domain for unrestricted use. Leveraging Alloy Therapeutic's ATX-Gx™ human transgenic mouse platform in parallel with genetically engineered DiversimAb™ mice,
Abveris, Inc. ("Abveris") announced today that it has entered into an antibody discovery partnership with Saccharo, Inc. ("Saccharo") for the discovery of monoclonal antibodies to advance the Saccharo therapeutic pipeline
Abveris, Inc. ("Abveris") announced today that it has entered into an agreement with Immunitas Therapeutics, Inc. ("Immunitas") for the discovery of monoclonal antibodies to expand the Immunitas therapeutic pipeline. Under the terms of the agreement, Abveris will utilize its proprietary DiversimAb TM mouse model in combination with
Abveris, a leader in contract research antibody discovery, today announced the promotion of Tracey Mullen from Chief Operating Officer to Chief Executive Officer (CEO), effective July 13, 2020.
Abveris Announces Human Antibody Discovery Partnership with Nkarta using the Trianni Mouse® on the Berkeley Lights Beacon®
May 12, 2020 12:13 UTC Abveris Announces Human Antibody Discovery Partnership with Nkarta using the Trianni Mouse ® on the Berkeley Lights Beacon ® CANTON, Mass.--( BUSINESS WIRE )-- Abveris, Inc. (“Abveris”) announced today that it has entered into an antibody discovery partnership with Nkarta, Inc. (“Nkarta”) for the discovery of fully-human monoclonal antibodies to support the advancement of Nkarta’s novel cell-based therapeutics. Under the terms of the agreement, Abveri
Abveris and Harbour Antibodies H2L2 BV Announce Technology Co-Offering Agreement for Fully Human Antibody Discovery
Abveris, Inc., a global leader in contract research antibody discovery, and Harbour Antibodies H2L2 BV, a wholly-owned subsidiary of Harbour BioMed, today announced a partnership to offer fully-human antibody discovery service that combines Abveris’ antibody discovery services with the Harbour H2L2 human transgenic mouse platform.
Abveris will be launching a sister company, AbX Biologics, with an exclusive focus on therapeutic antibody discovery services.
Abveris, Inc., a leader in contract research antibody discovery, announced that it has entered into a multi-target agreement with TetraGenetics, Inc.